Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United Kingdom based Director operating in the Biotechnology space. If you think a Director is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Paul Agapow
Health Informatics Director of AstraZeneca
Originally a labcoat-wearing biochemist and immunologist, Paul fell sideways into using computers for biology, at first for evolutionary biology and infectious disease. In more recent years, his work has focused on precision medicine and biomedical analytics.
Follow Paul Agapow:
About AstraZeneca: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
_______
Vincenzo Garzya
Patient Centricity Excellence Director of AstraZeneca
Follow Vincenzo Garzya:
About AstraZeneca: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
Claus Bendtsen
Executive Director of AstraZeneca
Claus Bendtsen heads Quantitative Biology as part of Discovery Sciences within AstraZeneca. His department provides global support in areas of informatics, mathematical modelling, image analytics and non-clinical statistics. Prior to joining AstraZeneca he held positions at Novartis and Merck & Co. Earlier in his career he co-founded three start-ups and worked in academia. He holds a Ph.D. in applied mathematics and an MBA.
Follow Claus Bendtsen:
About AstraZeneca: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
Sheena Behn
Global Supply Director of AstraZeneca
Sheena Behn is an established global leader in the Pharmaceutical Industry with significant supply chain, manufacturing and development experience and expertise. She has worked at AstraZeneca for 20 years. Sheena is currently VP Therapy Area Supply (for CVRM/INA Therapy Areas) in Operations for AstraZeneca, and the Operations Executive Sponsor for Risk, based in the UK. She was previously based in Gothenburg as VP R&D Supply Chain (2013-2015), running the global group for Clinical Supply at AZ; and before that VP for Wuxi Manufacturing site for 3 years, based in China (2010-2012). Sheena is a Pharmacist who started her career working in London hospitals, before working in pharmaceutical development with GSK and then AZ before joining Operations in 2007.
Follow Sheena Behn:
About AstraZeneca: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
Matthew Bonam
Pharmaceutical Project Director of AstraZeneca
Follow Matthew Bonam:
About AstraZeneca, AstraZeneca, AstraZeneca: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
Louise Almond
Associate Director, Process Sciences of Allergan
Follow Louise Almond:
About Allergan, Pharmaron: Allergan is a global pharmaceutical company.
Chris Bonnett
Projects Director of GE Healthcare
Chris Bonnett is a project director at GE Healthcare.
Follow Chris Bonnett:
About GE Healthcare: GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care.
Richard Ross
Founding Director & CSO of Diurnal Group
Richard Ross is a founding Director of Diurnal and Chief Scientific Officer and is contracted to perform work for the Group by the University pursuant to the terms of a secondment agreement and a research agreement. He is a Professor of Clinical Endocrinology and Head of the Academic Unit of Diabetes, Endocrinology and Metabolism at the University of Sheffield and was previously a Senior Lecturer at St. Bartholomew’s Hospital, London. Richard’s primary research interest is pituitary and adrenal disease with a particular focus on hormone replacement. His research has yielded over 200 papers, more than 30 granted patents and publications in Nature Medicine, Nature Reviews Endocrinology, Nature Genetics, The Lancet, The BMJ and PNAS. He has been a member of the editorial boards of Clinical Endocrinology and the Journal of Clinical Endocrinology and Metabolism and served as an elected member of the executive committees for the European Society of Endocrinology (Treasurer), the Society for Endocrinology and Growth Hormone Research Society.
Follow Richard Ross:
About Diurnal Group, University of Sheffield: Diurnal Group is an innovative pharmaceutical company creating high-value therapeutic drugs for use in the endocrine hormone area.
Ilaria Grizzi
Director, System Integration of Illumina
Follow Ilaria Grizzi:
About Illumina: Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Clive G. Brown
Directorships of Oxford Nanopore Technologies
Clive is Chief Technology Officer at Oxford Nanopore. On the Executive team, he is responsible for all of the Company’s product development activities. Clive leads the specification and design of the Company’s nanopore based sensing platform, including strand DNA/RNA sequencing and protein sensing applications with a strong focus on scientific excellence and successful adoption by the scientific community. Clive joined Oxford Nanopore from the Wellcome Trust Sanger Institute (Cambridge, UK) where he played a key role in the adoption and exploitation of ‘next generation’ DNA sequencing platforms. This involved helping to set up the world’s largest single installation of Illumina (formerly Solexa) Genome Analyzers in a production sequencing environment, initially used to pioneer the 1000 genomes project. From early 2003 he was Director of Computational Biology & IT at Solexa Ltd, where he was central to the development and commercialisation of the Genome Analyzer (GA). Solexa was sold to Illumina for $650M in early 2007 after the successful placement and adoption of 12 instruments. The Solexa technology, now commercialised by Illumina, is the market leading DNA sequencing technology driving the renaissance in DNA based discovery. He has a strong background in computer science and genetics/molecular biology and manages interdisciplinary teams including mechanical engineering, electronics, physics, surface chemistry, electrophysiology, software engineering and applications (of the technology). Clive applies modern agile management techniques to the entire product development lifecycle. Clive has also held various management and consulting positions at GlaxoWellcome, Oxford Glycosciences and other EU- and US-based organisations. He has worked at the interface between computing and science, ranging from genetics to proteomics. He holds degrees in Genetics and Computational Biology from the University of York.
Follow Clive G. Brown:
About Oxford Nanopore Technologies, Solexa: Oxford Nanopore Technologies develops nanopore-based electronic systems for analyzing single molecules, including DNA, RNA, and proteins.
Victoria Stewart
Director Of Communications of Abingworth
Victoria has more than 18 years experience in the life sciences sector. She manages and advises on Abingworth’s public relations strategy in Europe and the US and provides support to portfolio companies. Victoria joined Abingworth in 2000 from PJB Publications, where she was Biotechnology Editor of Scrip World Pharmaceutical News. Victoria has held editorial positions at Chemistry in Britain and the Financial Times, where she covered Pharmaceutical Business News, Biotechnology Business and Medical Device Business News. She has a degree in Biological Chemistry from the University of Kent at Canterbury.
Follow Victoria Stewart:
About Abingworth: Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs.
Helene Finney
Director, Functional Screening of UCB
Helene joined UCB (then Celltech) in 1989 after 2 years at the MRC Laboratory of Molecular Biology Cambridge, and has gained expertise in a range of antibody technologies. Her PhD studies at UCB in gene therapy generated the first co-stimulation signal inclusive (now termed “second generation”) CAR-T cell constructs. She has led a variety of antibody technology teams & early stage therapeutic antibody discovery projects for oncology, bone, immunology/inflammation & CNS targets. Helene now leads the UCB Functional Screening project team; combining cutting edge antibody & screening technology to discover break-through bispecific antibody drugs across multiple therapeutic areas.
Follow Helene Finney:
About UCB, UCB: UCB Pharma is a biopharmaceutical and specialty chemical company.
Heresh Rezavandi
Ecosystem Strategic Intelligence Lead, Associate Director of UCB
Heresh Rezavandi is the associate director of ecosystem strategic alliance at [UCB Pharma](https://www.crunchbase.com/organization/ucb-pharma), a biopharmaceutical and specialty chemical company that develops therapeutics for central nervous system and immunological diseases.
Follow Heresh Rezavandi:
About UCB: UCB Pharma is a biopharmaceutical and specialty chemical company.
Gavin Wild
Associate Director of UCB
Follow Gavin Wild:
About UCB: UCB Pharma is a biopharmaceutical and specialty chemical company.
Anne Lenihan
Director Regulatory Affairs of Pfizer
Follow Anne Lenihan:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Jeremy Farrar
Director of Wellcome Trust
Former Director, Oxford University Clinical Research Unit, Vietnam, with research interests in infectious diseases, tropical health and emerging infections. 2013, joined the Wellcome Trust; currently, Director. Fellow: Academy of Medical Sciences; The Royal Society. Recipient of numerous awards and honours, including: appointed OBE for services to Tropical Medicine (2005); Memorial Medal and Ho Chi Minh City Medal, Government of Vietnam. Named 12th in the Fortune list of 50 World’s Greatest Leaders in 2015.
Follow Jeremy Farrar:
About Wellcome Trust: Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health.
Lynsey Flitton
Associate Director Labeling Strategy Europe of AbbVie
Follow Lynsey Flitton:
About AbbVie: AbbVie is a pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and small molecule drugs.
Dennis Engelke
Executive Director, Country Manager Switzerland & Austria of Jazz Pharmaceuticals
Dennis Engelke is the director of business analysis and insight at [Jazz Pharmaceuticals](https://www.crunchbase.com/organization/jazz-pharmaceuticals), an international biopharmaceutical company. Engelke holds an MBA from Uppsala University and an MBA from the University of Hamburg.
Follow Dennis Engelke:
About Jazz Pharmaceuticals: Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments.
Anna C. Catalano
Board of Director of Mead Johnson Nutrition
Ms. Catalano, age 54, joined the Board on July 21, 2006 and currently serves as a member of the Company’s Governance Committee and Compensation Committee. She was Group Vice President, Marketing for BP plc from 2001 to 2003. Prior to that she held various executive positions at BP and Amoco, including Group Vice President, Emerging Markets at BP; Senior Vice President, Sales and Operations at Amoco; and President of Amoco Orient Oil Company. She currently serves on the Board and the Governance Committee of Mead Johnson Nutrition and Chemtura Corporation and the Compensation Committees of Mead Johnson Nutrition, Chemtura Corporation and Kraton Performance Polymers. She serves on the Executive Committee of the Houston Chapter of the Alzheimer’s Association and serves as a director on the National Board of the Alzheimer’s Association. Ms. Catalano formerly served on the boards of SSL International plc, Hercules Incorporated, Aviva plc and U.S. Dataworks and as an advisory board member of BT Global Services. Ms. Catalano holds a BS degree in Business Administration from the University of Illinois, Champaign-Urbana.
Follow Anna C. Catalano:
About : Mead Johnson Nutrition manufactures and sells infant formula, children’s nutrition, and other nutritional products.
Simon Bennett
Director, International Regulatory Affairs of Biogen Idec
Follow Simon Bennett:
About Biogen Idec: Biogen Idec is an American biotechnology company that provides therapeutics for neurological, autoimmune, and rare diseases.
Michael Brennan
Co Founder & Non-Executive Director of BenevolentAI
Mr. Michael Brennan co-founded BenevolentAI Limited in 2013 and serves as its Head of Corporate Development. Mr. Brennan co-founded Novum Securities in 2006 and served as it Chief Executive Officer. In 2009, Mr. Brennan joined Proximagen Group plc, as Head of Corporate Development, where he was focused on fund raising, corporate transactions and business development. Mr. Brennan has over 14 years of equity capital markets experience in the City focusing on the small and mid cap market. He is a Senior corporate finance executive with over 15 years City based capital markets experience. The majority of his time was spent with Evolution Securities where he served as a Director in their corporate finance department and has significant transactional experience including M&A and takeover work. He has been a Non-Executive Director at Litebulb Group Limited since September 13, 2013.
Follow Michael Brennan:
About BenevolentAI, SimplyPayMe: BenevolentAI is a developer of artificial intelligence and computational medicine technologies.
Ken Mulvany
Founder & Board Director of BenevolentAI
Mr. Ken Mulvany is a serial entrepreneur and investor with more than 20 years of business leadership experience. He is the Founder and Chairman of BenevolentAI, a $2bn machine intelligence company with end-to-end drug development capabilities. Mr. Mulvany was previously Founder and CEO of Proximagen, a leading biotech company developing medicines for central nervous system disorders, which he sold in 2012. Mulvany sits on several advisory boards including the advisory panel to the UK Government on Artificial Intelligence and the Advisory Board for Oxford Sciences Innovations. He is a member of the All-Party Parliamentary Group on Artificial Intelligence, and formerly, the Chairman of the Trustees of the Cure Parkinson’s Trust. Mr. Mulvany is a world champion sailor and competed in the 1992 America’s Cup.
Follow Ken Mulvany:
About BenevolentAI: BenevolentAI is a developer of artificial intelligence and computational medicine technologies.
Tom Holgate
Finance Director of BenevolentAI
Mr. Tom Holgate is Group Finance Director of BenevolentAI Ltd. He is responsible for all financial aspects of the Group including operational, reporting, strategy, planning and forecasting, transaction support and investor relations. Prior to joining BenevolentAI, he held senior positions at American Express), FP & A (Amlin Plc) and EY.
Follow Tom Holgate:
About BenevolentAI: BenevolentAI is a developer of artificial intelligence and computational medicine technologies.
Ray Edgson
Director of evonetix
Follow Ray Edgson:
About evonetix: Evonetix is a provider of a desktop platform designed to synthesize DNA at unprecedented accuracy and scale.
Simon Barter
Commercial Director of Proveca
Simon Barter is a commercial director at Proveca. Simon is an experienced pharmaceutical professional having held several significant senior level roles including the head of Global Marketing capability for AstraZeneca, the head of the Global Commercial Innovation function. He has a track record of delivery in global marketing, innovation, corporate and portfolio strategy and operating company delivery. He has broad therapeutic experience having led the commercial therapy areas for Pain, Anaesthesia, Infection and Oncology. Simon has lived and worked across several European countries in sales and marketing roles, amassing first hand experience of several healthcare systems. Simon has a BSc (Hons) from London University and a Masters in Science of Management from Boston University.
Follow Simon Barter:
About Proveca: Proveca Ltd is a UK based pharmaceutical company.
Andrew Shepherd
Co-Founder & Managing Director of Omega Diagnostics
Andrew Shepherd is the Founder and Managing Director of Omega Diagnostics Limited. He is responsible for corporate strategy, general management, sales and marketing and technical direction. He has been involved in the medical diagnostics industry for the last 35 years. He started his career in 1974 by holding technical positions at G.D. Searle Limited and then attended university, graduating with a Bachelor of Science in Biology. He then moved into a sales and marketing position at Cambridge Life Sciences plc in 1981, before establishing his first diagnostics company, Cambridge Biomedical Limited in 1982. In 1986 he moved to Scotland to join Bioscot Limited and shortly afterwards, established Omega. Shepherd used his technical experience and knowledge of exporting to oversee the growth of the export of Omega products to exceed £2 million per annum. Omega now exports to over 100 countries around the world, and he travels regularly to many of the countries in which Omega customers are based. Shepherd is an active member of a number of relevant trade associations and was a member of the Scottish Exports Forum, a body which reported to the Scottish Parliament to oversee and guide the export activity of Scottish Development International. Mr Shepherd was also a member of the Bill & Melinda Gates Foundation’s (BMGF) Global Health Diagnostics Forum, which provides direct guidance to BMGF in advising on future investments in worldwide diagnostics programmes for developing countries.
Follow Andrew Shepherd:
About Global DX Ltd, Omega Diagnostics: Omega Diagnostics provides IVD products for use in hospitals, blood banks, clinics, and laboratories.
Andrew Barker
Co-Founder & Director of Intelligent Ultrasound
Andrew Barker is the Chairman at Oxford Brain Diagnostics .
Follow Andrew Barker:
About Anchard Associates, Brainomix, Intelligent Ultrasound, Oxford Brain Diagnostics: Intelligent Ultrasound develops software that improves the quality, reliability, and diagnostic power of medical ultrasound.
Chris Wood
Non Executive Director of MiNA Therapeutics
Chris Wood has more than 20 years of experience in the biotechnology sector, having founded, managed and successfully exited 4 companies. Chris is Executive Chairman and Medical Director of NuCana. He was co-founder, Chairman and CEO of Bioenvision Inc from 1999, and under his leadership Bioenvision grew from a modest entrepreneurial venture to a leading biotech company (NASDAQ: BIV), with a market capitalisation of $345 million. Bioenvision was acquired by Genzyme Corporation in October 2007. Chris was co-founder of Medirace Ltd, a start up biotechnology company, which later became Medeva PLC, traded on the London Stock Exchange and the New York Stock Exchange, and was acquired by Celltech Group PLC (now UCB) for £554 million. Chris Wood is an honorary Professor at Imperial College London, holds an M.D. from the University of Wales School of Medicine and is a Fellow of the Royal College of Surgeons of Edinburgh. Chris Wood’s specialty interests are Cancer and Molecular Biology and he has acquired an international reputation for his published work in these areas.
Follow Chris Wood:
About Medannex Ltd, NuCana BioMed: MiNA Therapeutics is a clinical-stage biotechnology company developing therapeutic medicines to harness gene activation mechanisms.
Tim Luker
Senior Director, External Innovation, Global External R&D of Eli Lilly
Follow Tim Luker:
About Eli Lilly: Eli Lilly engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment.
Derek Marren
Director – Research IT – Global TA & Biology systems & Data Integration of Eli Lilly
Follow Derek Marren:
About AstraZeneca, Eli Lilly: Eli Lilly engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment.
Richard Whitley
Member of the Board of Directors of Gilead Sciences
Whitley joined Gilead’s Board of Directors in 2008. He is a Distinguished Professor, Loeb Scholar Chair in Pediatrics; Director, Division of Pediatric Infectious Diseases; Vice-Chair, Department of Pediatrics; Senior Scientist, Department of Gene Therapy; Senior Scientist, Cancer Research and Training Center; Associate Director for Clinical Studies, Center for AIDS Research; and Co-Director, Center for Emerging Infections and Emergency Preparedness (CEIEP) for the institution. Whitley has held responsibility for the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group, is a past President of the International Society of Antiviral Research, chairs the Board of Scientific Counselors for the National Center for Infectious Diseases of the U.S. Centers for Disease Control and Prevention and is President of the Board of the Infectious Diseases Society of America.
Follow Richard Whitley:
About : Gilead Sciences is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for critical diseases.
Kruti Popat
Director, Customer Insights & Engagement of Galapagos
Follow Kruti Popat:
About Galapagos: Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel.
Colleen Johnson
Associate Directorof Toxicology & Consultant of Spinifex Pharmaceuticals
Colleen brings over 20 years of experience in the area of toxicology. She holds a M.S. in Toxicology from University of Arizona as well as Board Certification (D.A.B.T.) and specializes in the development of nonclinical toxicology testing programs for new drugs. Her activities include preparation of toxicology summaries for Spinifex’s submissions in support of our development candidates, develops study protocols and monitors the company’s toxicology programs.
Follow Colleen Johnson:
About Spinifex Pharmaceuticals: Spinifex Pharmaceuticals is a clinical-stage biotechnology company specializing in the development of products for the treatment of pain.
Ed McDermott
Co-Founder and Managing Director, UK of EMMAC Life Sciences
Ed McDermott is the co-founder and managing director at EMMAC Life Sciences.
Follow Ed McDermott:
About EMMAC Life Sciences: EMMAC is a medical cannabis company that works to join together the latest science and research with cutting-edge cultivation.
Danilo Casadei Massari
Board of Directors of TargEDys
Follow Danilo Casadei Massari:
About BCD Bioscience, Nemysis: TargEDys develops functional food, medical food and medical products to harness the microbiota’s ability to regulate appetite.
Alan Barrell
Non-Executive Director of Eagle Genomics
Alan Barrell has spent almost 30 years in senior executive positions in technology based industries and has become one of Cambridge’s most articulate promoters of entrepreneurship. He was a founder shareholder in Library House Ltd, and is now Entrepreneur in Residence at the University’s Centre for Entrepreneurial Learning and Visiting Professor of Enterprise at the University of Bedfordshire School of Graduate Business Studies. He is also Distinguished Guest Professor at Xiamen University, Visiting Professor at Shanghai College of Science and Technology and at the Fujian International School of Economics and Business, Fuzhou, all in China. He has taught at Tsinghua University Beijing and Minjiang University, Fuzhou City. Other appointments include Senior Enterprise Fellow, University of Essex, International Fellow, Anglia Ruskin University Cambridge, and International Fellow, Laurea University of Applied Sciences in Helsinki.
Follow Alan Barrell:
About Cambridge Associates, Eagle Genomics: Eagle Genomics is a enterprise software solutions company to enable the management, orchestration and exploitation of life sciences data.
Jonathan Tobin
Managing Director of Arix Bioscience
Jonathan specialises in therapeutics and diagnostics investments and has a background in medical research and drug discovery. Prior to joining Imperial Innovations he worked at MRC Technology, sourcing and evaluating new opportunities for small molecule and antibody drug discovery worldwide. He has a PhD in molecular medicine from UCL, and undertook post-doctoral research at the Cancer Research UK LRI. He has published in journals including New England Journal of Medicine, Nature Genetics, and PNAS. Jonathan has a First Class degree in Biological Science from Oxford University and an MBA with Distinction from Imperial College.
Follow Jonathan Tobin:
About Arix Bioscience: Arix Bioscience is a healthcare and life science company.
Nick Bolas
Founder & Director of Hallmarq Veterinary Imaging
Nick Bolas is the Founder and Director at Hallmarq Veterinary Imaging Ltd.
Follow Nick Bolas:
About Hallmarq Veterinary Imaging: Hallmarq Veterinary Imaging is a global leader in innovative diagnostic imaging.
Richard Durbin
Informatics Director of Congenica
Richard is a Group Leader of the Human Genetics Programme at the Wellcome Trust Sanger Institute, a Fellow of the Royal Society, and a Member of EMBO. A pioneer in the industry, he has developed sequence data analysis tools that are now standards in the field. His current research focuses on human genetic variation by large scale genome-wide re-sequencing. Richard has led the international 1000 Genomes Project and the UK10K Genome Project, and has made significant contributions to the Ensembl resource for vertebrate genome annotation, and the TreeFam and Pfam databases.
Follow Richard Durbin:
About Congenica: Congenica is a biotechnology company that provides a diagnostic decision support platform.
Matthew Hurles
Scientific Director of Congenica
Matt is Senior Group Leader at the Wellcome Trust Sanger Institute and a leader in the Deciphering Developmental Disorders, 1000 Genomes and UK10K projects. He has pioneered the analysis of whole exomes in clinically relevant disorders that previously failed diagnostic methods, and has led an initiative to characterise structural variation in the human genome, and integrate this knowledge into disease and population genetic studies. Matt has been awarded the Balfour Lecture by the Genetics Society and the Crick Lecture prize for accomplishments in genetics by the Royal Society.
Follow Matthew Hurles:
About Congenica: Congenica is a biotechnology company that provides a diagnostic decision support platform.
Philip Beales
Medical Director of Congenica
Phil is a consultant physician and Professor of Medical and Molecular Genetics at the UCL Institute of Child Health (ICH), an NIHR Senior Investigator, an Honorary Consultant in Clinical Genetics at Great Ormond Street Hospital (GOSH) and the lead on Personalised Medicine for UCL. He is an internationally recognized expert in the genetics and pathogenesis of ciliopathies and pioneering use of next generation sequencing in mapping disease genes in this area.
Follow Philip Beales:
About Congenica: Congenica is a biotechnology company that provides a diagnostic decision support platform.
Hazel Gorham
Director – Biosimilars Development of PRA Health Sciences
Follow Hazel Gorham:
About PRA Health Sciences: PRA Health Sciences provides product development and data solution services to pharmaceutical and biotechnology companies.
Robert Perin
Managing Director of Protak Scientific
Prior to his current role as CEO & partner at Protak Scientific in the biotechnology industry the last 5 years, Robert Perin worked at Blackberry as Senior Commercial Director, Europe for just under a decade.
After his time in telecommunications, he worked as an investor and advisor for several start-ups including launching Oscobo, Becovi Media and CST Automotive amongst others. Since becoming CEO and partner in one of the most exciting and ground changing Biotech companies to date, Robert has been instrumental in bringing major pharma companies onboard such as Pfizer, Bayer, Novo Nordisk, and AstraZeneca.
Protak Scientific provides rapid validation solutions to large isolator manufacturers, global pharmaceutical companies, and scientific universities with established and recognised ground-breaking technology that assists pharmaceutical companies to validate their decontamination in aseptic production.
He has been key to both setting the corporate strategy and gaining international recognition and acceptance, as the innovative way of approaching validation, with the regulators and international scientific community.
He has also been a key part in the expansion of the company globally into countries such as the US, India, and China, trebling revenue in recent years. Although relatively new to the pharmaceutical industry, his belief in the technology, passion for the industry, and commercial acumen have enabled Protack Scientific to become a growing UK success story within the international pharmaceutical industry.
Follow Robert Perin:
About Protak Scientific: PS is a biotechnology firm that manufacturers enzyme indicators.
Shankar Balasubramian
Co-Founder and Director of Cambridge Epigenetix
Sir Shankar is Founder of two companies and the principal inventor of the leading next generation human genome sequencing technology core to all Illumina sequencing platforms, estimated to be worth >$30BN. Sir Shankar’s technology has made routine, accurate, low-cost sequencing of human genomes a reality, has revolutionised biology and accelerated the development of genomic personalised medicine. Sir Shankar is the Herchel Smith Professor of Medicinal Chemistry at the University of Cambridge and Senior Group Leader at the Cancer Research UK Cambridge Institute. His awards include the Royal Medal (2018), the RoyalSociety Mullard Award (2009), The BBSRC Innovator of the year (2010) and the Tetrahedron Prize (2013). He is a Fellow of the Royal Society, the Academy of Medical Sciences and a member of EMBO.
Follow Shankar Balasubramian:
About Ahren Innovation Capital, Cambridge Epigenetix: Cambridge Epigenetix is using epigenetics to reduce several routine & important diagnostic tests for common cancers to a simple blood draw.
Martin Murphy
Associate Director of Cambridge Epigenetix
Follow Martin Murphy:
About Cambridge Epigenetix: Cambridge Epigenetix is using epigenetics to reduce several routine & important diagnostic tests for common cancers to a simple blood draw.
Courtney Nicholson
Director Of Business Development of Abcam
Follow Courtney Nicholson:
About Abcam: An innovator in life science reagents and tools serving life science researchers globally to achieve their mission, faster.
Ajan Reginald
Executive Director & Co-Founder of Cell Therapy
Follow Ajan Reginald:
About Celixir, Cell Therapy: Cell Therapy Ltd is a British pioneer in Regenerative Medicine.
Dominic Falcao
Founding Director of Deep Science Ventures
Founding Director at Deep Science Ventures
Follow Dominic Falcao:
About Deep Science Ventures: DSV is a venture studio and a fund that develops a systematic, optimized approach to science company development and investment.
Mark Hammond
Founding Director of Deep Science Ventures
Mark manages the commercialisation of software including web and mobile apps. Since joining the technology transfer team in 2011 he has founded the Imperial Digital Enterprise Accelerator and built a community of student entrepreneurship around the accelerator under the icstartup brand. This initiative drives venture creation via workshops, talks, funding and mentorship from experienced entrepreneurs in collaboration with both College initiatives and student societies. Mark completed a combined Masters in Neuroscience and Artificial Intelligence from UMIST and went on to obtain a PhD whilst leading a project which investigated how networks of neurons generate behaviour by implementing a biological neuronal network as the brain of a mobile robot. He has also been featured in New Scientist and given talks at the Science Museum and Dana Centre. Marks commercial background includes setting up an IT service business unit and an analyst role at a boutique investment bank in which he worked with IT and cleantech start-ups to develop their commercial and fundraising strategy.
Follow Mark Hammond:
About Deep Science Ventures: DSV is a venture studio and a fund that develops a systematic, optimized approach to science company development and investment.
Chris Jones
Non Executive Director & Special Advisor of MediSieve
Chris Jones joined Elasmogen as Executive Chairman in 2016.
Follow Chris Jones:
About Elasmogen, MediSieve, Mologic: MediSieve is a therapeutics company developing a platform technology for the treatment of blood-borne diseases.
Berwyn Clarke
Non Executive Director of PBD Biotech
Berwyn is an experienced senior manager in the pharmaceutical and diagnostics industry. In 2005 he founded a new diagnostics company in the UK, Lab21 Limited, prior to establishing network of diagnostics industry interests in 2013. He is currently Chairman of NALIA Systems Ltd and PBD Biotech Ltd and non-executive director at Protein Logic. He is currently also Entrepreneur-in-Residence at Cardiff University and is a senior advisor to the Welsh Government Life Sciences sector.
Follow Berwyn Clarke:
About Glyconics, PBD Biotech: PBD Biotech specialises in novel phage-based diagnostics for the veterinary, agriculture and human health sectors
Ben Swift
Director of Research and Development of PBD Biotech
Follow Ben Swift:
About PBD Biotech: PBD Biotech specialises in novel phage-based diagnostics for the veterinary, agriculture and human health sectors
Himanshu Kataria
Founder, CEO and Managing Director of CLYZ Labs
Himanshu is an experienced NHS Academic Clinician with emergency medicine background (>10 years clinical experience). Himanshu has substantial experience in setup and delivery of clinical research trials, as a specialty lead within Clinical Research Network for the whole of North West Coast of England delivering research in >23 NHS Partner organisations. Himanshu is an MBBS, MBBS, MRCSed (A&E), MRCEM, FRCEM, ALS Instructor. With a number of years in both clinical and research experience, Himanshu has held various consultancy posts in notable hospitals/medical facilities such as Whiston Hospital in Merseyside. He also held the Special Group Lead position within the Clinical Research Network – North West Coast: Research Delivery arm of the NIHR (National Institute of Health Research). In addition to his qualifications as a Medical Doctor, Himanshu has held a number of entrepreneurial roles over the past few years in bio-medical companies such as Indu Stem Cell Technology Plc, and Transgenex Inc in the USA. Dr Kataria is familiar with financial management of the business owing to his experience in Clinical Finance Limited which advised for fundraising for Indu Stem Cell Technology PLC. He continues to serve as a director for Indu Stem Cell Technology PLC.
Follow Himanshu Kataria:
About CLYZ Labs: CLYZ Labs are developing a testing service to select the best drug therapy for personalised cancer treatment.
Adrian Fisher
Director and Co-Founder of Stemnovate
Co-founder and director, Adrian Fisher has over 20 years experience in the design, development, and application of integrated Microsystems, covering areas ranging from energy storage through to biological analysis. Adrian Fisher heads the electrochemical and micro engineering group in Cambridge in the Centre for Research in Electrochemical Science and Technology, and also within the Campus for Research Excellence and Technological Enterprise in Singapore.
Follow Adrian Fisher:
About Stemnovate: Drug Screening and Safety Testing Platforms
David Hay
Director and Co-Founder of Stemnovate
A Professor of Tissue Engineering at the University of Edinburgh, co-Founder and Director David Hay has earned a long-standing reputation for his work in stem cell biology and hepatocyte differentiation. David Hay believes that a trans-disciplinary approach is needed to solve the failings that currently exist in the cell microenvironment. David Hay is actively involved in the translation of stem cell derived hepatocytes into scalable manufacturing processes, by defining culture conditions and developing physiologically relevant models.
Follow David Hay:
About Stemnovate: Drug Screening and Safety Testing Platforms
Ozgur Tuncer
CEO & Executive Director of Stablepharma Ltd
Ozgur Tuncer CEO & Executive Director – two decades of experience in the biopharmaceutical industry including working for blue chip companies such as Pfizer, IQVIA and Pharmacia. Most recently, he was Global Vice President in IQVIA, and strategic adviser to life sciences investors. In addition to his role in Stablepharma, Özgür is an Investment Partner with Ascension Ventures.
Follow Ozgur Tuncer:
About Stablepharma Ltd: An innovative Biotech, developing a wide range of reformulated thermostable and fridge free StablevaX vaccines
Paul Race
Director and Co-Founder of Zentraxa
Paul is Senior Lecturer in Biochemistry at the University of Bristol. From 2014-17 he served as Co-Director of the >£14M Bristol Centre for Synthetic Biology Research (BrisSynBio), was a founding Director of the Bristol BioDesign Institute (BBI) and is academic lead for the >£2.7M EPSRC funded ‘Manufacturing Immortality’ project. His research focuses on the exploitation and manipulation of biological complexes, pathways and networks, en-route to the development of new tools, technologies and products for biotechnology.
Follow Paul Race:
About Zentraxa: Zentraxa has specialise in the design, production and testing of complex novel peptides.
Elodie Siney
Director and Co-Founder of VisusNano
Elodie is a research scientist with expertise in human stem cells, completed the integrated PhD programme at the University of Southampton specialising in human stem cells for translational research. Elodie worked in an SME as a chemical analyst and has experience in clinical trials.
Follow Elodie Siney:
About VisusNano: Revolutionising Treatment for Cataracts
Kathryn Millett
Director of Biosecu.re
Kathryn Millett is the Director of Biosecure, a company dedicated to safeguarding the bioeconomy, and strengthening biosecurity through education, training and policy advocacy.
Follow Kathryn Millett:
About Biosecu.re: Biosecu.re helps ensure a resilient, safe, and secure environments, frameworks, and processes.
Adam George
UK Managing Director of GW Pharmaceuticals
Adam George has served as our Managing Director – UK since March 2017. Mr. George also acts as our Company Secretary. Prior to taking on his current role, Mr. George served as our Chief Financial Officer since 2012 and Financial Controller since 2007. Mr. George has previously occupied several senior finance roles within both public and privately-owned companies, most recently as Finance Director from 2004 to 2007 and as Group Financial Controller from 2001 to 2004 of Believe It Group Limited (now 4Com plc), a telecommunications service provider. Mr. George holds an BSc. in Biology from Bristol University and is qualified as a chartered accountant.
Follow Adam George:
About GW Pharmaceuticals: GW Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics.
Gil McVean
Co Founder & Director of Genomics
Gil McVean is Professor of Statistical Genetics at the University of Oxford and Head of Bioinformatics and Statistical Genetics at the Wellcome Trust Centre for Human Genetics. After an undergraduate training in Zoology, he obtained a PhD with Laurence Hurst in Cambridge and worked with Brian and Deborah Charlesworth in Edinburgh before joining Oxford in 2000. His research focuses on understanding the molecular and evolutionary processes that shape genetic variation in populations and the relationship between genetic variation and phenotype. He has made contributions to our understanding of areas including recombination hotspots, historical patterns of natural selection, the male mutation rate, human genetic variation, the role of HLA in complex disease and genealogical processes. He has played a leading role in the HapMap and 1000 Genomes Projects and currently works on organisms from HIV to malaria.
Follow Gil McVean:
About Genomics: Genomics plc aiming to lead the genomic transformation of healthcare.
Gary Muirhead
CEO, Director and Founder of Ixchelsis
Gary MuirheadGary graduated in Applied Biology from Cardiff University in 1979 and then trained and was employed as a Clinical Biochemist at the University Hospital of Wales and Surrey County Hospital through to 1986. Gary then joined Roche as a Team Leader and Senior Scientist, Pharmacokinetics/Drug Metabolism. In 1993 Gary joined the Pfizer Clinical Pharmacology group in Sandwich and held positions of increasing responsibility over the subsequent 14 years. As well as managing the Clinical Pharmacologists and providing strategic leadership in the GI, GU/Sex Health and Anti-viral therapeutic areas, Gary was also the Global Clinical Pharmacology lead for a number of successful drugs including Viagra, Celsentry®, and Geodon®. Gary also acted as Early Clinical Leader for a number of GU/Sex Health projects during this period. In 2006 Gary was appointed Sandwich Site Head for Clinical Research Operations and successfully built a group responsible for the operational delivery of exploratory development, clinical pharmacology and clinical technology clinical studies. In June 2009 Gary was appointed to the position of Vice President, Clinical Affairs Site Head for Specialty Care in Sandwich. In this position Gary managed the clinicians, statisticians and clinical pharmacologists, ensuring the provision of quality resources to the Asset Teams. Gary is now Founder and Chief Executive Officer of Ixchelsis Ltd a Pfizer Sandwich Start-up focusing on developing drugs in Men’s Health indications.
Follow Gary Muirhead:
About Ixchelsis: Ixchelsis develops an oxytocin receptor antagonist for the treatment of premature ejaculation.
Peter Jackson
Director of Redag Crop Protection
Dr. Peter Jackson, also known as Pete, is a Co-Founder of Redx Pharma PLC, RedAg Crop Protection Ltd., ADC Biotechnology Ltd., YProTech Ltd and Reaxa Ltd. Dr. Jackson has over twenty five years’ experience in the sector including the commercialisation of innovative technologies and forming, funding, development and exiting of technology startups. He is a serial life sciences entrepreneur based in the North West of England. He served as Vice President of Piramal Healthcare UK Limited (also known as NPIL Pharmaceuticals (UK) Limited and Avecia Pharmaceuticals Limited) since 2002. He held a series of sales and business management roles in the UK, Europe and Japan with ICI and Zeneca. He served as the Chief Executive Officer of Reaxa Ltd. He serves as the Non-Executive Chairman at BiVictriX Therapeutics Ltd. He serves as the Chairman of YProTech Ltd. He provides YProTech with valuable strategic guidance and commercial support. He served as the Chairman of the Board at Redx Pharma Plc. He serves as a Director of Blackley Holdings Ltd, ADC Biotechnology Ltd. and Yorkshire Process Technology Ltd. He served as a Non Executive Director of Redx Pharma Plc since September 2014 until March 31, 2017. Dr. Jackson is a Graduate of the Universities of East Anglia, UK and Massachusetts USA, Dr. Jackson gained his PhD at Durham University, UK before joining ICI Fine Chemicals in 1989.
Follow Peter Jackson:
About AMR Centre, Redag Crop Protection: The engine of discovery for the agrochemical industry.
Denise Devenny
Director of Plant Operations of Celtic Renewables
Denise Devenny serves as director of plant operations at Celtic Renewables.
Follow Denise Devenny:
About Celtic Renewables: Celtic Renewables is a biofuel startup focused on the renewable energy and whisky sector.
Stewart McGarrity
Finance Director of Celtic Renewables
Stewart McGarrity serves as finance director at Celtic Renewables.
Follow Stewart McGarrity:
About Celtic Renewables: Celtic Renewables is a biofuel startup focused on the renewable energy and whisky sector.
Oliver Kessler
Founder, Medical Director and Chief Medical Officer of Orthox Ltd.
Oliver Kessler is a practising knee surgeon based in Zurich with a strong track record of biomaterials research and a focus on meniscal and cartilage repair systems and joint kinematics. He spent 6 years at Stryker Orthopaedics as Director of Orthobiologics supervising a major meniscal tissue engineering programme. He has extensive contacts within both the orthopaedic industry and the surgical community and is responsible for overseeing clinical development of Orthox’s product pipeline.
Follow Oliver Kessler:
About Orthox Ltd.: Orthox develops tissue regenerative implants that address large injuries to cartilage tissues in which early osteoarthritis may be present.
Sarah Nurse
Operations Director of Orthox Ltd.
Sarah Nurse is an experienced Operations and Finance Director with the skills to create and manage a corporate services function. She has over 20 years experience incorporating start ups and growing SME companies; ensuring full financial and management accounting control, and managing human resource, information technology and quality assurance functions in both the public and private sectors.
Follow Sarah Nurse:
About Orthox Ltd.: Orthox develops tissue regenerative implants that address large injuries to cartilage tissues in which early osteoarthritis may be present.
Jonathan Steele
Director of Finance of Evodental
Follow Jonathan Steele:
About Evodental: EvoDental, a dental implant center, provides dental implant treatment solutions.
Karen Roy
Chief Strategy Officer & Member of the Board of Directors of Phlexglobal
Karen Roy graduated as a Pharmacist in South Africa and entered the Pharmaceutical Industry working for Eli Lilly in Sales. In 1992, she moved into Clinical Research in the UK with Chiltern International, initially managing the Clinical Development Department. Latterly she started up and globally managed a new and novel group, EDC Solutions. In 2007, Karen joined Phlexglobal as Chief Business Development Officer and moved into her current role as Senior Vice President, Client Solutions in 2015. With her clinical and EDC background, Karen has also taken on a lead role in Phlexglobal’s electronic Trial Master File initiative, to promote, develop and implement support of Client eTMF systems as well as Phlexglobal’s eTMF Solution – PhlexEview. Karen also co-chairs the DIA TMF Reference Model, an industry driven initiative to standardize the content, naming and structure of Trial Master Files.
Follow Karen Roy:
About Phlexglobal: Established in 1997 Phlexglobal delivers a specialist comprehensive service for all administrative aspects of the clinical trial process
Jenny Tillotson
Founder & Creative Director of eScent
Jenny Tillotson is the creator and driving force behind eScent, an enabling platform technology and delivery device that emits precise doses of fragrances at the right time, in the right place, depending on context. This is highly scalable technology for sensing and dispensing scent and liquids, providing a new sensory awareness with wide‐ranging applications in fashion, fragrances for luxury brands, wellbeing, digital health, AR/VR, retail, sports, entertainment, learning and adult industry. Jenny spent 14 years at Central Saint Martins, University of the Arts London developing her award-winning eScent research and was made a Reader in Sensory Fashion in 2013. More recently Jenny has moved to commercialise her research. She formed a company that works at the intersection of fashion, fragrance, smell and wearable technology, co-founded with Professor Andreas Manz, a pioneer of lab-on-a-chip and winner of the EU ‘lifetime achievement’ inventor award for patents on microchip technology for chemical applications. Jenny’s involvement over the past year has specifically been in the area of fine fragrance for the fashion industry and digital health for stress and sleep disorders with a particular focus on leveraging disparate data sources to discover more accurate health-related correlations. The company holds 4 granted patents and 1 pending patent that creates an exclusive market position on wearable sensory data collection related to the sense of smell, pharma and insect control. Jenny has a degree in Fashion Communication from Central Saint Martins and a PhD in interactive olfactory surfaces (Printed Textiles) from the Royal College of Art. She has been a Fellow of the of the Royal Society of Arts since 2009, a Fellow of the Winston Churchill Memorial Trust since 2013 and an Associate of the British Society of Perfumers since 2005. Jenny is also a Visiting Scholar in the Institute of Biotechnology at the University of Cambridge and a STEM Ambassador. Prior to her academic work she was a fashion stylist in the media and worked as a Sensory Designer for Charmed Technology (MIT Media Lab spin-off). She has exhibited internationally, published in science and design journals, consulted for NIKE, Unilever, INTEL, Qualcomm, Toyota and worked with Philips, Cambridge Consultants, The North Face, Adeline André and International Flavours & Fragrances.
Follow Jenny Tillotson:
About eScent, The Royal Society for the encouragement of Arts, Manufactures and Commerce (RSA): Wearable technology and sensory data collection for preventative healthcare.
Matthew Ainslie
Director DevOps & Cloud Engineering of PAREXEL
Matthew Ainslie serves as director of cloud engineering and devops at PAREXEL.
Follow Matthew Ainslie:
About PAREXEL: PAREXEL is a biopharmaceutical services company that focuses on the development and commercialization of new medical therapies worldwide.
Angela Williams
Assoc. Director of Feasibility & Proposals of Synexus
Prior to joining Synexus in 2015 as the Associate Director of Feasibility and Proposals, Angela was a global feasibility manager for a large CRO. There she conducted the largest-ever feasibility investigator outreach, resulting in a successful client deliverable. She gained her nursing qualification from the University of Sheffield and took up a post as an oncology nurse at Christie Hospital in Manchester. She finished her nursing career in 2005 as the lead Breast Cancer Research Nurse at the Royal Preston Hospital where she quickly identified potential recruitment opportunities across two other hospital sites. This led to an increase in patient recruitment and future research opportunities for the trust. Upon leaving the NHS, Angela was a Site Lead within a large CRO, setting up a network of GP surgeries and hospitals to widen the inclusion of participating doctors in research studies. She also has sales and marketing experience as the Product Manager for Ophthalmology, Infections, Pain, Diabetes, Oncology and Surgery in a large pharma company. Angela successfully identified potentially new segments of the market to place her products and motivated the sales team to increase market share.
Follow Angela Williams:
About Synexus: Synexus is a site network organization that continues to pioneer important developments in the clinical trials industry.
Phyllis Sheppard
Senior Director of Quality of Synexus
Phyllis has 26 years experience in the pharmaceutical industry in the CRO, SMO and company sectors, spanning sales, clinical research, GCP auditing and Quality. Phyllis joined Synexus in 2015 as a Senior Director of Quality and is delighted to be consolidating all aspects of quality across the Synexus Organisation.
Follow Phyllis Sheppard:
About Synexus: Synexus is a site network organization that continues to pioneer important developments in the clinical trials industry.
Stoyan Smoukov
Co-Principal Investigator & Board of Directors of Xanofi
Stoyan was co-principal investigator in the development of the Xanofi technology. He holds a PhD in Chemistry from Northwestern University. Stoyan has 10 years of polymer research and engineering experience and the past 6 years spent specifically on nanoscience and nanofiber technology.
Follow Stoyan Smoukov:
About Queen Mary University of London, Xanofi: Xanofi is a nanotech company specializing in the production of nanofiber applications.
Jonathan Hollick
Managing Director of Breakpoint Therapeutics
Follow Jonathan Hollick:
About Breakpoint Therapeutics: Breakpoint Therapeutics is a company that discover and develop new anti-cancer drugs.
Susan Searle
Non-Executive Director of Horizon Discovery
Susan Searle is Chief Executive Officer of Imperial Innovations Group plc, an AIM listed company founded by Imperial College. Imperial Innovations is an integrated business combining the activities of technology transfer, incubation and investment across healthcare, engineering, environment and IT sectors. Susan has been instrumental in growing the business since joining the Ltd company in 1994. Previously she worked at Montech (Australia), Signet Group plc, Bank of Nova Scotia and Shell Chemicals Limited in the UK and internationally in a variety of business development and commercial roles. She has served on the boards of 15 spin-out companies including TurboGenset Inc. and sits on the boards of Thiakis Limited, EVO Electric Limited and i2india Holdings Limited. She has an MA in Chemistry from Exeter College, Oxford University.
Follow Susan Searle:
About : Horizon is a gene editing company that designs & engineers genetically-modified cells, applying them to advance human health.
Mick Hunter
Chief Scientific Officer & Director of Development of Atopix Therapeutics
Dr Mick Hunter has responsibility for drug discovery and development in Atopix. He has over 28 years experience in Pharmaceutical and Biotech R&D. He has spent the past 12 years working on the discovery and development of antinflammatory and respiratory drugs. He is also Director of Discovery at Oxagen Ltd. Mick has led Atopix CRTH2 antagonist discovery and development program from concept to Phase IIb. Less Mick has experience of leading teams to identify IND candidates and managing them through early clinical development. He is familiar with regulatory environments and has managed biological pilot plants for GMP manufacture. Prior to joining Atopix, Mick held positions at Oxagen Ltd, British Biotech Pharmaceuticals (now Vernalis PLC) and at Searle Pharmaceuticals.
Follow Mick Hunter:
About Atopix Therapeutics: Atopix Therapeutics Limited is a privately held, clinical-stage, biopharmaceutical company based in Oxford, UK
Monika Tomecka
Executive Director, CEO & Co-Founder of uFraction8
Dr Monika Tomecka has a PhD with a background in biology, genetics and biomedical research. This gives her insight into the science and operations of uFraction8’s customer segments. She is able to converse at an appropriate level to engage and sell the benefits of uFraction8 technology.
Follow Monika Tomecka:
About uFraction8: uFraction8 develops microfluidics-based filtration systems to help bio-manufacturers to harvest biomass sustainably and more efficiently.
Brian Miller
Managing Director & Co-Founder of uFraction8
Dr Brian Miller is one of the original inventors of uFraction8’s technology. Following the successful PhD where the technology was developed, he undertook a Royal Society of Edinburgh Enterprise Fellowship to learn the skills required for commercialisation of the technology. Furthermore, he has a background as a professional engineer and was involved in delivering high value projects in gas turbine control systems in industry.
Follow Brian Miller:
About uFraction8: uFraction8 develops microfluidics-based filtration systems to help bio-manufacturers to harvest biomass sustainably and more efficiently.
Banafshe Larijani
Co-founder, Joint Managing Director and CSO of Fastbase Solutions
Banafshe Larijani holds a PhD in Molecular Cell Biology and Biochemistry, Amherst College, and the University of Massachusetts at Amherst, Massachusetts, USA. Head of Cell Biophysics Laboratory since 2002 at Cancer Research UK, she was appointed Senior Scientist in 2012 and in 2014 was awarded the Ikerbasque Research Professorship. She holds adjunct professorships with University of Bath (UK), Stony Brooks University NY and University of Massachusetts, Amherst MA, (USA). Her laboratory is a cutting-edge cross-disciplinary platform, which draws upon the physical sciences to develop novel avenues for investigation of biological processes in signalling. The outcomes of her fundamental research involving the application of quantitative imaging (FRET-FLIM) for investigating molecular mechanisms of various oncoproteins have resulted in their application to clinical objectives. Cell Biophysics is now at the Biophysics Institute Insituto Biofisika) and Research Centre for Experimental Marine Biology and Biotechnology (PiE) in Bilbao, Spain.
Follow Banafshe Larijani:
About Fastbase Solutions: Fastbase Solutions is a cancer diagnostics platform.
Ian Warwick
Director of Liverpool ChiroChem
Ian Warwick is the Managing Partner at Deepbridge Capital LLP.
Follow Ian Warwick:
About AlgaeCytes, arbnco Limited, Deepbridge Capital, Liverpool ChiroChem: Liverpool ChiroChem manufactures and supplies specialist building blocks for pharmaceutical research and biotechnology.
AF_initDataCallback({key: \’ds:1\'” alt=”” class=”wp-image-14850″ width=”154″ height=”152″/>Roy Lobb
Director and Co-founder of Aleta Biotherapeutics
Roy Lobb is the Director and Co-founder at Aleta Biotherapeutics.
Follow Roy Lobb:
About Advent Life Sciences, Aleta Biotherapeutics: Aleta Biotherapeutics focuses on transforming cellular therapeutics to allow a broader spectrum of cancer indications to be targeted.
Chris Dowle
Director of the National Biologics Manufacturing Centre of Centre for Process Innovation
In April 2013, Chris was appointed in his new role as Director of CPI’s £38 million National Biologics Manufacturing Centre. The centre will help UK companies to develop new processes and products and embrace and test new and emerging technologies in the growing biopharmaceutical market. Chris has worked at CPI as a director since the day it began trading to helping companies and organisations test, develop and scale up sustainable processes, products and energy solutions. His practical and commercial approach enables customers to sustain competitiveness and enter valuable and new markets as quickly as possible. In Chris’ career he has worked internationally helping companies take from laboratory concepts to world scale plant. Following his PhD at the University of Strathclyde in 1988, Chris joined ICI as a research chemist and then developed his technical career across a range of roles from separations technology through to plant operations support and then moved into new disciplines in, engineering and biotechnology. Chris has also been involved in managing GLP laboratories, moving through into commercial business development and management.. Chris has also worked for engineering and process technology licensing companies. He has sectorial experience of pharmaceuticals, chemicals, materials, and biotechnology. Some publications and patents are held, but Chris has mainly delivered process and technology packages to clients for their interpretation. Chris has presented widely at conferences and has been called on to collaborate and work on relevant themes in and for the UK’s IB-IGT, BBSRC, EIBI, Europabio, Star-COLIBRI and the ETI.
Follow Chris Dowle:
About Centre for Process Innovation: The CPI is a technology innovation center helps its clients develop, prove, prototype, and commercialize products and processes.
Neville Hamlin
Financial Director and Chief Operating Officer of Centre for Process Innovation
Neville holds board directorships and company secretary positions for the CPI group of companies. A professional qualified chartered accountant with an MBA, he has over 25 years experience in the semiconductor and hi-tech industry with over 20 years in senior management and board positions. Neville has established key start-up companies in the North East of England: he set up the Siemens Microelectronics facility in 1995, moving from Siemens HQ in Germany to do so, and he established Atmel’s manufacturing site in the UK in 2000; he has taken a biofuel company to AIM listing and has also been involved in several MBOs/MBIs. He established a Nanotechnology Centre of Excellence (Cenamps) in 2003 and was instrumental in obtaining the funding to establish CPI’s Printable Electronics Centre at NETPark and was responsible for the design and building programme. Neville possesses a broad knowledge of business start-up and development, financial engineering, multi-national trading structures, and public vs. private sector drivers. He joined the newly merged CPI organisation from Cenamps in April 2008 as Finance Director and Chief Operating Officer.
Follow Neville Hamlin:
About Centre for Process Innovation: The CPI is a technology innovation center helps its clients develop, prove, prototype, and commercialize products and processes.
Sophie Walton
Director Of Strategic Partnerships of Centre for Process Innovation
Follow Sophie Walton:
About Centre for Process Innovation: The CPI is a technology innovation center helps its clients develop, prove, prototype, and commercialize products and processes.
Tom Taylor
Director, Future Business of Centre for Process Innovation
Tom is a Senior Industrial Innovation Manager with 20 years experience of high technology product and business development. He has a materials technology background and his focus has been on integrating novel materials into industrial scale processes. He specialises in enabling clients to bring products to market quickly and cost effectively whilst managing risk through a thorough understanding of the specific needs of industry. Tom has collaborated intensively with the plastic electronics community, having been on the board of the Organic Electronics Association, the Printed Electronics Leadership Group and the Cambridge University IKC Industry Board. Tom works closely with government organisations such as BIS, TSB and ESP KTN in defining strategy for the commercialisation of innovation in printable electronics in the UK. In addition, he also helps clients to win venture capital funds, as well as funding for collaborative projects. He is always looking to bring new entrants into the printable electronics field. Previously Tom was Head of the chemicals business at Frost & Sullivan and held senior market and operational rolls at ICI, where he was responsible for businesses in the UK, France and Thailand. He has a Chemistry DPhil from Oxford University.
Follow Tom Taylor:
About Centre for Process Innovation: The CPI is a technology innovation center helps its clients develop, prove, prototype, and commercialize products and processes.
Jon Helliwell
Operations Support Director of Centre for Process Innovation
Follow Jon Helliwell:
About Centre for Process Innovation: The CPI is a technology innovation center helps its clients develop, prove, prototype, and commercialize products and processes.
Sally Adams
Development Director of Scancell
Dr. Sally Adams was Head of Neurology & Virology at British Biotech and Development Director at Neures Limited before becoming an independent consultant providing drug development and management services within the biotechnology and pharmaceutical sectors, specializing in biological entities. She has worked on many complex projects over the past 25 years including anti-infective vaccines, cancer immunotherapies and an innovative stem cell treatment for visual dysfunction. Sally previously worked as a development consultant to Scancell, providing guidance on the development of SCIB1, before her appointment as Development Director in May 2014.
Follow Sally Adams:
About Scancell: Scancell is focused on developing innovative immunotherapies for cancer that stimulate the body’s own immune system.
Jasbir Singh
Managing Director of HEL LTD
Follow Jasbir Singh:
About HEL LTD: HEL Ltd is a provider of automated and manual tools to clients in the pharmaceutical, and chemical industries.
Philipp Kukura
Founder and Director of Refeyn
Philipp Kukura is the Founder and Director at Refeyn.
Follow Philipp Kukura:
About Refeyn: Refeyn is specialising in label-free single molecule imaging and mass measurement.
Bijendra Patel
Director of Surgical Skills and Science of Barts Cancer Institute
Follow Bijendra Patel:
About Barts Cancer Institute, Barts Health NHS Trust: Barts Cancer Institute (BCI) is one of the top cancer research centres in the UK.
Samantha Perona
CEO, Founder & Director of Perfectus Biomed
Experienced Chief Executive Officer, PhD, MSC with a demonstrated history of working in commercial research. Skilled in Good Laboratory Practice (GLP), ISO 9001 and 17025. Experience with FDA 510K data generation and MDD/MDR compliance. Strong business development professional with a Goldman Sachs 10,000 small businesses focused in Business.
Follow Samantha Perona:
About Perfectus Biomed: Perfectus Biomed is a U.K.-based biotechnology company providing microbiological services.
Apostolos Papadopoulos
Managing Director of Crop Intellect
Dr. Apostolos Papadopoulos founded Crop Intellect in November 2011, since which he has been serving as its managing director.
Follow Apostolos Papadopoulos:
About Crop Intellect: Crop Intellect operates a research and development company that develops agricultural technologies that improves crop productivity.
Matt Worrall
Associate Director, Policy & Communication – Oncology of MSD
Matt has more than a decade of healthcare media relations and public affairs experience gained across medical professional bodies, NHS and provider sector. Before joining Portland he was a public affairs executive at ABPI and was Head of Communications at the Royal College of Surgeons. He saw the College through its engagement with the Health & Social Care Act 2012 and high-profile campaigning for the relaxation of the European Working Time Directive. Among his clients in recent years have been the NHS National Screening Committee, NHS England, BMI Healthcare, HCA International, Lilly, Amgen, UCB, Mundipharma, Apple and Alexion.
Follow Matt Worrall:
About MSD: MSD is a leading global biopharmaceutical company that provides medicines, vaccines, biologic therapies, and animal health products.
Ian Abercrombie
Business Unit Director & Chief Operating Officer of NuCana BioMed
Ian Abercrombie has over 25 years experience in the biopharmaceutical and healthcare industry. Ian’s specific expertise includes the clinical development and commercialisation of anti-cancer medicines and companion diagnostics to enable therapies to be targeted to specific patient populations. Ian has wide biopharmaceutical and healthcare experience having initially served in the public health sector before working for Janssen Cilag, Ortho-Biotech, Bioenvision and Caris Life Sciences. Whilst at Bioenvision, Ian played a major role in developing and commercialising clofarabine, the first new drug to be approved specifically for childhood acute leukaemia in Europe for over thirty years.
Follow Ian Abercrombie:
About Medannex Ltd, NuCana BioMed: NuCana BioMed, a biopharmaceutical company, develops and commercializes rationally designed medicines for significant unmet medical needs.
John Bernard
Marketing Director, EMEA of Dexcom
John Bernard EMEA Marketing Director UK Marketer of the Year 2013. Marketing ‘Vision 100’ 2014. Shortlisted ‘Digital Marketer of the Year 2014’. Founder (1996) and CEO of successful housing start-up sold in 2007. Investor. Board Member x 2.A multiple award-winning, commercially focused marketer, with an ability to use customer insight to create powerful marketing solutions. A bright, confident and self-motivated individual with a track record of using marketing to exceed specified global annual targets of over €1 billion revenue. Henley MBA qualified, with over 20 years’ telecoms, media and technology experience. Speciality of launching products into market using advertising, PR, product marketing, digital, channel activity and sponsorship. Over ten years’ experience of managing marketing budgets of over £15m successfully to exceed sales targets. Not just experience with old-school marketing, though. Expert online marketer who know how to create a buzz through inbound marketing or viral traffic through the web, social media and content discovery. Writing a good press release just doesn’t cut it anymore so now also an industry blogger who understands how the current state of the web operates and knows how to make it work. Enjoy working at both the strategic and tactical levels, developing people and teams, owning and improving business performance both internationally and within the UK. Currently the EMEA Marketing Director of Dexcom.
Follow John Bernard:
About Dexcom, MENA Digital Awards: Dexcom develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management.
Kat Bruce
Co-founder and Managing Director of Nature Metrics
Kat Bruce is the Co-founder and Director of NatureMetrics.
Follow Kat Bruce:
About Nature Metrics: Nature Metrics is an award-winning technology start-up using cutting-edge genetic techniques to monitor biodiversity.
Irina Soltamova Solovyev
Director of Cambridge Oncometrix
Follow Irina Soltamova Solovyev:
About Cambridge Oncometrix: Cambridge Oncometrix aims to save lives by enabling the early detection of prostate cancer.
Maxim Rossmann
Managing Director of Cambridge Oncometrix
Follow Maxim Rossmann:
About Cambridge Oncometrix, University of Cambridge: Cambridge Oncometrix aims to save lives by enabling the early detection of prostate cancer.
David Bunka
Director & CTO of Aptamer Group
Dave holds a Ph.D. in Molecular Biology from the University of Leeds and is a Geneticist by training. He spent 12 years developing high throughput automated aptamer selection methods at the University of Leeds. David has built up a solid international reputation in the field. Since 2003 David has isolated ~200 aptamers against a wide variety of targets including: small molecule antibiotics, food contaminants, disease associated proteins, several cancer associated cell-lines, viruses and patient tissue samples. Since joining the group officially in 2012 David had developed over 50 aptamers to various targets and has development several patentable process variations. David has authored several aptamer papers in peer reviewed journals, including 2 invited review articles and a book chapter in 2012 for the Royal Society of Chemistry entitled “therapeutic uses of nucleic acid aptamer conjugates”.
Follow David Bunka:
About Aptamer Group: Aptamer Group develop DNA and RNA nucleic acid aptamers for use in R&D, biomarker discovery, diagnostics or therapeutic developments.
